Cover Image
close this bookFact sheet No 180: Variant Creutzfeldt-Jakob disease (vCJD) - Revised December 2000 (WHO, 2000, 4 p.)
View the document(introduction...)
View the documentTotal Cases
View the documentEpidemiology
View the documentClinical Features
View the documentDiagnosis
View the documentProbable Cause
View the documentEvidence of vCJD-BSE Link
View the documentOther Human TSEs
View the documentMeasures Taken to Protect Public Health
View the documentWorld Health Organization (WHO) Involvement
View the documentWHO Recommendations

World Health Organization (WHO) Involvement

· Since 1991, WHO has convened nine scientific consultations on issues related to animal and human TSEs. These meetings have made wide-ranging recommendations aimed at protecting human and animal health.

· As exposure to the BSE agent may extend to populations outside Western Europe, it was recommended that to ascertain the number and distribution of any future cases, global surveillance of CJD and its variants would be required.

· From 1997-2000, WHO held a series of training courses worldwide, particularly in developing countries, with the intention of helping individual countries establish national surveillance of CJD and its variants. The first workshop, for West African countries, was held in Dakar, Senegal in June 1997. Similar workshops were held in Bangkok for Southeast Asian countries (October 1997), in Cairo for North African countries (February 1998) and in China for countries of the Western Pacific (July 1999) and for Eastern and Central European countries in May 2000. Another is planned for Mediterranean countries.